Dsuvia
Total Payments
$29,923
Transactions
36
Doctors
29
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $4,757 | 27 | 25 |
| 2022 | $25,165 | 9 | 7 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $26,750 | 2 | 89.4% |
| Consulting Fee | $2,000 | 1 | 6.7% |
| Food and Beverage | $1,173 | 33 | 3.9% |
Payments by Type
Research
$26,750
2 transactions
General
$3,173
34 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Plastic Surgery Education Study | AcelRx Pharmaceuticals, Inc. | $25,000 | 0 |
| Orthopedic Education Study | AcelRx Pharmaceuticals, Inc. | $1,750 | 0 |
Top Doctors Receiving Payments for Dsuvia — Page 2
Ad
Manufacturing Companies
- AcelRx Pharmaceuticals, Inc. $29,923
Product Information
- Type Drug
- Total Payments $29,923
- Total Doctors 29
- Transactions 36
About Dsuvia
Dsuvia is a drug associated with $29,923 in payments to 29 healthcare providers, recorded across 36 transactions in the CMS Open Payments database. The primary manufacturer is AcelRx Pharmaceuticals, Inc..
Payment data is available from 2022 to 2023. In 2023, $4,757 was paid across 27 transactions to 25 doctors.
The most common payment nature for Dsuvia is "Unspecified" ($26,750, 89.4% of total).
Dsuvia is associated with 2 research studies, including "Plastic Surgery Education Study" ($25,000).